BCL2 and cancer: Notably, Mcl-1 is responsible for the resistance to the new generation of BH3 mimetic cancer therapies, including ABT-737 and ABT-263, which bind to the anti-apoptotic proteins Bcl-2, Bcl-xL and Bcl-w to disrupt their interaction with the pro-apoptotic Bcl-2 family members [46,47,48].